Evidence map›Paper›PMID 37755279›Full record

ArticleMetabolites2023

Influence of Symbiotic Fermentation Broth on Regulating Metabolism with Gut Microbiota and Metabolite Profiles Is Estimated Using a Third-Generation Sequencing Platform.

Chih-Yin Wu, Chun-Kai Huang, Wei-Sheng Hong, Yin-Hsiu Liu, Ming-Chi Shih, Jung-Chun Lin

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Gut Microbiota-Targeted Intervention of Hyperlipidemia UsingPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chih-Yin WuDepartment of Family Medicine, Wan Fang Hospital, Taipei Medical University, Taipei City 116, Taiwan.ORCID 0000-0001-6002-3608
Chun-Kai HuangDepartment of Laboratory Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.
Wei-Sheng HongSagittarius Life Science Corporations, Taipei 115, Taiwan.
Yin-Hsiu LiuSagittarius Life Science Corporations, Taipei 115, Taiwan.
Ming-Chi ShihSagittarius Life Science Corporations, Taipei 115, Taiwan.
Jung-Chun LinSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, New Taipei City 235, Taiwan.ORCID 0000-0003-3781-1504
Wan Fang Hospital · TW

Funding

Ministry of Education, Taiwan 110-6603-005-400Sagittarius Life Science Corporations, Taiwan A-111-008
6 · The paper itself

Abstract

Overnutrition with a high-fat or high-sugar diet is widely considered to be the risk factor for various metabolic, chronic, or malignant diseases that are accompanied by alterations in gut microbiota, metabolites, and downstream pathways. In this study, we investigated supplementation with soybean fermentation broth containing saponin (SFBS, also called SAPOZYME) in male C57BL/6 mice fed a high-fat-fructose diet or normal chaw. In addition to the lessening of weight gain, the influence of SFBS on reducing hyperlipidemia and hyperglycemia associated with a high-fat-fructose diet was estimated using the results of related biological tests. The results of gut microbial profiling indicated that the high-fat-fructose diet mediated increases in opportunistic pathogens. In contrast, SFBS supplementation reprogrammed the high-fat-fructose diet-related microbial community with a relatively high abundance of potential probiotics, including

Indexed as

gut metabolitegut microbiotaLC-MS/MSMetaCyc databaseONT sequencingsymbiotic fermentation broth

Identifiers

PMID37755279
PMCPMC10535509
OpenAlexW4386601125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.